Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ki Health Partners LLC DBA New England Institute for Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$272,291

144 payments

Through program year 2025, Ki Health Partners LLC DBA New England Institute for Clinical Research is reported as receiving $272,291 in research payments, across 144 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $54,699 80
2024 Research $49,036 20
2023 Research $88,685 33
2022 Research $62,858 9
2021 Research $17,013 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. Biohaven Pharmaceutical Holding Company Ltd. $156,027 52 payments
  2. Pfizer Inc. $46,516 76 payments
  3. H. Lundbeck A S $37,313 9 payments
  4. Biohaven Pharmaceuticals, Inc. $17,013 2 payments
  5. Upsher-Smith Laboratories LLC $15,421 5 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 4 Randomized Doubleblind Placebocontrolled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use $90,162 73 payments
  2. A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With A History of Inadequate Response to Oral Preventive Medications $73,237 50 payments
  3. A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease $23,644 3 payments
  4. Real World Effectiveness of Eptinezumab in Participants With Migraine (Evec) $20,838 6 payments
  5. A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease $17,013 2 payments
  6. An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United States $16,476 3 payments
  7. P255-501 $8,183 4 payments
  8. A Phase 4 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for Migraine Prevention in Treatment Resistant Subjects $7,750 1 payment
  9. A Phase 4 Randomized Double-Blind Placebo Controlled Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Subjects with Cardiovascular Contraindication to Triptans High Cardiovascular Risk or Triptan Resistant Subjects $7,750 1 payment
  10. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy(R) XR in the Prevention of Migraine in Children 6 to 11 Years of Age $7,239 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record